Cellectis shares slump as death puts cell therapy tests on hold

LONDON (Reuters) - French cell therapy specialist Cellectis, which is developing a gene-modified cancer treatment similar to Novartis's recently approved Kymriah, has been forced to suspend testing following a patient death.